

Anti-Cancer Drugs 2007

Key Word Index to Volume I8

- 10058-F4, 161
13-*cis*-retinoic acid, 597
15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂, 65
17-allylamino-17-demethoxygeldanamycin, 875
1-nitroacridine, 87
2'-deoxyadenosine, 301
5-bromo-2-deoxyuridine, 1053
5-fluorouracil, 17, 263, 581, 597, 781, 1103
6-mercaptopurine, 839
7-keto- Δ^3 -steroids, 997
- A549, 65
actinic keratoses, 357
actinomycin D, 763
acute lymphoblastic leukaemia, 941
acute myeloid leukemia, 323, 641
adenosine monophosphate-activated protein kinase, 405
ADH1, 563
adjuvant, 297
adjuvant chemotherapy, 821
advanced breast carcinoma, 843
advanced colorectal cancer, 709, 955
advanced gastric cancer, 605
Akt, 677, 913
Akt inhibitors, 861
angiogenesis, 1, 341, 349, 563, 1005
antagonist, 525
antagonists and inhibitors, 105
anthracycline, 493
anthracycline cardiomyopathy, 1081
anthracyclines, 883
anti tumor drug, 1023
antiangiogenesis, 1
antiangiogenic therapy, 569
antibody, 127
anti-cancer, 171
anticancer, 41
anticancer drug, 311, 317
anticancer drugs, 111, 499
antiestrogens, 923
Antiferritin antibodies, 725
antileukemic, 839
antileukemic activity, 997
antineoplastic agents, 323, 487
antineoplastic combined chemotherapy protocol, 703
antioxidative enzymes, 389
antiproliferation, 1133
antiproliferative, 525
antiproliferative activities, 1069
antiproliferative activity *in vitro*, 447
antiproliferative effect, 1039
antitumor, 127
anti-tumor activity, 875
antivascular activity, 905
apoptosis, 41, 47, 79, 139, 179, 187, 197, 333, 363, 535, 555, 659, 669, 763, 913, 981, 1023, 1045, 1081, 1123, 1133, 1139, 1149, 1165
apoptosis signaling kinase I, 649
ARC-111, 435
area under the curve, 17
aromatase inhibitors, 923
asparagine-glycine-arginine (NGR), 1189
ATP, 543
ATP-based tumour chemosensitivity assay, 1093
ATP-binding-cassette transporters, 389
- B steroidal lactams, 997
Bax, 1139
Bcl-2, 1139
Bcl2, 65
Bcl-2, 2, 755, 763, 913
Bcl-xL, 405
BCTIC, 171
bendamustine, 587, 697
bengamide B, 219
biliary drainage, 697
bilirubin, 693
biomarkers, 749
bis-targeting, 171
bivatuzumab mertansine, 477
biweekly, 1201
bladder, 745
bladder cancer, 357
bladder neoplasms, 487
BM-cyclin 1, 1015
bortezomib (PS341, Velcade), 677
brain metastases, 1227
brain metastasis, 23
breast cancer, 311, 419, 555, 773, 883, 923, 1113, 1213
breast cancer MCF-7, 467
busulfan, 333
- Ca²⁺, 649
Caco-2, 1081
calcipotriol, 447
calcitriol and its analogs, 447
calcium gluconate and magnesium sulfate, 721
calcium homeostasis, 55
captopril-bombesin conjugate, 341
cancer, 277, 363, 377, 525
cancer therapeutics, 237
cancer therapy, 861
capecitabine, 273, 597, 817, 831, 883
carboplatin, 471
carcinoma, 703
cardiomyopathy, 737
cardiotoxicity, 227
caspase, 65, 1139
caspase 7, 649
caspase, 913
CD13, 1189
celecoxib, 1075
cell cycle, 773, 981, 1113, 1133
cell line, 525
cell lines, 749
central nervous system relapse, 941
ceramides, 105
cerebrospinal fluid, 23
cervical cancer, 149
cetuximab (Erbix), 7
cetuximab, 827
chemoresistance, 371
chemosensitivity, 1093
chemosensitization, 755
chemotaxis, 1173
chemotherapy, 245, 581, 733, 737, 745, 749, 79, 831, 843, 87, 889, 955, 973, 1103, 1207
children, 277
chlorambucil, 301
chloroacetaldehyde, 543
chronic myeloid leukemia, 641
cisplatin, 187, 263, 311, 317, 411, 659, 755, 1123, 1213, 1227
cisplatin-refractory, 273
cladribine, 301
clonogenic death effect, 659
collagen gel droplet embedded drug sensitivity test, 17
colon cancer, 297, 317, 633, 733
- colorectal cancer, 7, 781, 973, 977, 1103
colorectal cancers, 55
colorectal carcinogenesis, 1183
comparative genomic hybridization, 87
complement, 1029
concentration in cerebrospinal fluid, 941
concomitant chemoradiotherapy, 713
connexin 43, 669
correlation analysis, 389
cosmesis, 357
CPT-11, 11, 605, 977
crossover, 1093
cudraflavanone A, 1023
cutaneous, 827
cyclooxygenase-2, 889
cytochrome C, 543
cytochrome C, 669
cytostatic compounds, 621
cytotoxic activity, 905
cytotoxic drugs, 389, 621
cytotoxicity, 301, 333, 1023
- D steroidal lactams, 997
day 1 every 3 weeks schedule, 587
delayed-action preparations, 283
dendrimers, 839
deoxycytidine, 487
desensitization, 721
disease-free survival, 821
DNA damage, 171, 1053
DNA double-strand break repair, 419
DNA topoisomerase, 1023
DNMT, lung cancer, metastasis, mithramycin A, 1157
docetaxel, 95, 211, 597, 745, 755, 883, 889, 1201, 1207, 1213, 1227
dopamine receptor, 801
doxorubicin, 1113, 1123, 419
doxorubicin toxicity, 737
drug delivery, 839
drug delivery systems, 283
drug development, 861
drug formulations, 95
drug resistance, 139, 633
drug response, 499
dual topoisomerase-I/II poisons, 139
ductal carcinoma *in situ*, 1231
- early and late apoptosis, 149
ECV304 cell, 1005
Eg5, 773
elderly, 713
EM-1421, 933
encapsulation, 839
enediynes-energized, 127
epidermal growth factor, 7
epidermal growth factor receptor inhibition, 171
epigenetic, 363
epirubicin, 227, 581, 687
epithelial, 525
epithelial to mesenchymal transition, 371
ERK (extracellular signal-regulated kinase), 913
ERk, 677
erlotinib, 1109
erythrocyte, 211
esophageal neoplasms, 703
estrogen receptor, 773
ethnic distribution, 693
extracellular domain, 949
extrahepatic bile duct cancer, 697
- familial Mediterranean fever, 733
farnesyltransferase inhibitor, 923
Fas ligand, 555
Fas receptor, 1139
Fas-Fas ligand, 187
Fas/APO-1, 555
fenretinide, 47
folinic acid, 781
functional test, 23
fusarochromanone, 897
fusion protein, 127
- G₁ checkpoint, 411
ganciclovir, 79
gastric cancer, 581, 677
gastric cancer BGC-823, 467
gastric carcinoma, 1075
gastrointestinal stromal tumor, 969
G-CSF, 687
gefitinib, 949
geldanamycin, 1173
geldanamycin analogue, 875
gemcitabine, 179, 211, 263, 745, 1109, 1207
gene expression, 1005
gene expression profile, 633
gene profiling, 499
genistein, 649
germ cell tumor, 273
glial fibrillary acidic protein, 669
glioblastoma, 621, 669
glioma, 875
glutathione, 389
gold compounds, 323
G-protein-coupled receptors, 801
growth inhibition, 801
Gymnocladus chinensis Baillon, 41
- H460, 65
haemodialysis, 977
head and neck cancer, 781
heat shock protein 70, 1165
helixor A, 1005
hematopoietic, 525
hemolytic anemia, 297
hepatocellular carcinoma, 161
hepatoma cells, 47
HER2, 949
HER2-overexpression, 23
histone, 363
histone deacetylase, 793
histone deacetylase inhibitor, 793
histone deacetylase inhibitor, 641
HL-60 cells, 1149
Hodgkin's lymphoma, 725
homologous recombination, 419
human cancer cell lines, 447
human cell lines, 897
human colon cancer cell line, 427
human epidermal growth factor, 827
human herpesvirus 4, 79
human osteosarcoma Saos-2 cells, 543
human telomerase reverse transcriptase, 161
human tumor cloning assay, 311, 317
hydridolithiation, 311
hydroxycamptothecin, 1045
hypoxia, 435
hypoxia-inducible factor-1 α , 435
- imatinib, 1029
imatinib mesylate, 969

- imatinib, 641
 immune cytopenia, 973
 immunohistochemistry, 883
 immunotherapy, 1221
 implanted mice hepatoma, 1133
 induction chemotherapy, 713
 ingenol 3-angelate, 357
 inhibitor, 363, 1023
 inhibitory protein of nuclear factor- κ B, 149
 interferon, 817
 interleukin-2, 291, 597, 817
 intestine, 197
 intracellular clusterin distribution, 55
 intralesional injection, 283
 in-vitro models, 749
 irinotecan, 197, 263, 605, 693
 isoindigos, 1069
- kinase inhibitory activities, 1069
 kinases, 237
 kinesin, 773
- L929 cells, 187
 LAF389, 219
 LAQ824, 793
 laryngeal neoplasms, 459
 laryngeal squamous cell cancer, 29
 LD₅₀, 87
 leiomyosarcoma, 745
 leucovorin, 597, 709, 1103
 leukemia, 357
 leukemia K562, 467
 leukotriene B₄ receptor antagonist, 535
 Lewis lung cancer, 467
 lidamycin, 127
 ligands, 237
 liposomes, 95
 liver function, 697
 lonafarnib, 923
 lung, 1053
 lung cancer, 713
 LY293111, 535
 lymphoma, 1029
 lytic path, 411
- macrophages, 187
 maintenance immunotherapy, 597
 MCF-7 xenograft, 311
 Mcl-1, 405
 medicinal inorganic chemistry, 323
 medullary thyroid carcinoma, 831
 melanoma, 897, 1221
 melanoma A375, 467
 melanoma B16, 467
 MET, 1173
 metastasis, 349, 371, 569
 metastatic breast cancer, 23, 477, 687, 963, 1213
 metastatic gastric cancer, 597
 methotrexate, 941
 microarray, 633
 microarray analysis, 499
 microsphere, 459
 microtubule-depolymerizing agent, 905
 microtubule-stabilizing agent, 905
 mitochondria, 1045
 mitochondrial membrane potential, 543
 mitomycin C, 709
 mitotic exit, 1053
 mitoxantrone, 233
 molecular targets, 861
 molecular therapy, 981
 MTHFR, 821
 multidrug resistance, 1015, 1075
 multidrug resistance protein 2, 1015
 multiple myeloma, 405
 mutagenicity, 411
 myelotoxic chemotherapy, 277
 myoglobin, 227
- nanoparticles, 95
 natural killer cells, 1029
 N-cadherin, 563
 necrosis, 543
 neoadjuvant, 745
 nephrotoxicity, 323
 neuroendocrine tumour, 1227
 neutropenia, 277
 NGR-liposomal doxorubicin, 1189
 nitric oxide, 149
 non-melanoma skin cancer, 357
 non-small cell lung cancer, 1201
 non-small cell lung cancer, 317, 755, 793
 non-small cell lung carcinoma A549, 467
 non-small-cell lung cancer, 471
 norcantharidin-Nd3II, 1133
 noscapine, 1139
 nuclear factor κ B, 677
 nuclear factor-kappa B, 179
 nuclear factor- κ B, 41, 149
 nucleoside esters, 301
- O⁶-methylguanine methyltransferase, 621
 oncohematological diseases, 301
 optimal regimen, 843
 osteosarcoma, 737
 ovarian, 1093
 ovarian cancer, 317, 889
 oxaliplatin, 297, 581, 633, 721, 1103
- p21^{WAF1}, 161
 p21, 363, 1113
 p27, 1113
 p38 mitogen-activated protein kinase, 649
 p53, 197, 555, 763, 1113
 paclitaxel, 227, 283, 459, 687, 703
 paclitaxel cetuximab, 835
 paclitaxel combination therapy, 933
 pancreatic cancer, 263, 535, 569, 1109
 panitumumab, 7
 parenteral formulation, 933
 patients with platinum-refractory relapse, 611
 patients with platinum-sensitive relapse, 611
 PC cell-derived growth factor, 29
 pegfilgrastim, 277
 pegylated interferon, 1221
 pegylated liposomal doxorubicin, 611
 peripheral blood lymphocyte, 763
 peroxisome proliferator-activated receptor γ , 237
 peroxisome proliferator-activated receptor- γ , 65, 525
 P-glycoprotein, 1075
 pharmacogenetics, 111
 pharmacogenomics, 499
 pharmacokinetics, 111, 283
 phase I, 219, 477, 587
 phase I study, 471
 phase II, 211, 263, 1213
 phase II clinical trial, 1221
 phase II study, 949
 phase I/II trial, 605
 phenylisocyanate of quercetin, 1165
 platinum, 1093
 poly(ADP ribose) polymerase, 1139
 poly(lactic-co-glycolic acid), 459
 polymers, 283
 polymorphisms, 821
 polysorbate 80, 95
 porfimer sodium, 1149
 precancerous lesions, 29
 preclinical toxicology, 87
 predictive, 1093
 predictive biomarkers, 499
 prevention, 897
- proaerolysin, 809
 prodrug, 301
 proliferation, 1123
 prostacyclin, 349
 prostate cancer, 87, 233, 341, 563, 949
 prostate-specific antigen, prostate cancer, 809
 proteasomal degradation and PI3K-AKT-mTOR signaling, 435
 protein kinase C, 1023
 proteome, 1045
 pterocarnin A, 555
 pulmonary metastases, 291
 Puma, 763
- QT interval, 493
 quantitative reverse transcription polymerase chain reaction, 499
 quercetin, 1165
- Rad51, 419
 radiation, 1, 659
 radioimmunotherapy, 725
 radiosensitizer, 1, 793
 radiotherapy, 969
 ralitrexed, 781
 randomized trial, 1093
 RB, 411
 reactive oxygen species, 149
 reduced glutathione, 149
 refractory, 245
 relapsed, 273
 relapsing epithelial ovarian cancer, 611
 renal carcinoma, 817
 renal cell cancer, 317
 renal cell carcinoma, 291
 resistance, 389, 1093
 rhabdomyosarcoma, 1173
 RhoGDI α , 333
 ribonucleotide reductase, 377
 ribosomal synthesis, 763
 rituximab, 1029
 RNA interference, 29, 377
 rodents, 87
- S-1, 1, 471, 605
 salvage, 487
 salvage chemotherapy, 709
 salvage therapy, 963
 sanguinarine, 913
 secondary leukaemia, 233
 second-line, 1201
 second-line therapy, 255
 selective estrogen receptor modulator, 1039
 senescence, 1053
 serum epidermal growth factor receptor, 949
 sex distribution, 693
 short interfering RNA, 377
 signal pathways, 237
 single-agent bendamustine, 963
 SK-7041 (glivec), 641
 skin cancer, 827
 skin metastases, 835
 SKOV-2, 1081
 Skp2, 1113
 small cell lung cancer cell, 801
 small interfering RNA, 333, 427
 small-cell lung cancer, 255
 small-molecule c-Myc inhibitor, 161
 Soblidotin, 905
 soft-tissue sarcoma, 245
 solid tumors, 587
 sonodynamic therapy, 1149
 S-phase arrest, 535
 sphingolipids, 105
 sphingosine 1-phosphate, 105
 sphingosine kinase-1, 105
 squamous cancer, 827
 squamous cell, 703
- Src, 371
 Src kinases, 981
 steroidal esters, 997
 STI571 (gleevec), 641
 stomach neoplasms, 79
 structure modification, 1165
 structure-activity relationship, 997
 structure/activity relationship, 1039
 SU5416, 349
 super hydride, 311
 superficial bladder cancer, 179
- T cell lymphoma, 1123
 tamoxifen, 1039
 targeted therapies, 255, 621
 targeted therapy, 477
 taxanes, 1213
 Taxotere, 95
 temozolomide, 621, 1227
 terameprocol, 933
 thalidomide, 1221
 therapeutic, 377
 therapeutic use, 323
 thiol, 543
 third-line, 817
 thrombospondin-1, 1005
 thymidine kinase mRNA, 1183
 thymidine phosphorylase, 883
 thymidylate synthase, 781
 titanocene, 311, 317
 topoisomerase I inhibitors, 435
 topoisomerase II α , 1015
 topoisomerase inhibitors, 255
 Torsades de Pointes, 493
 toxicity, 111, 697, 1109
 toxicity profiles, 955
 transitional cell carcinoma, 211, 487
 transketolase, 427
 transketolase activity, 427
 transketolase-like-1, 427
 trastuzumab, 23, 1231
 treatment, 897
 trichostatin A, 1005
 triple negative breast cancer, 835
 triterpenoid saponin, 41
 troponin, 227
 tumor, 897
 tumor cloning assay, 317
 tumor growth, 1173
 tumor necrosis factor-tumor necrosis factor receptor 1, 187
 tumor perfusion, 905
 tumor progression, 371
 tumorigenesis, 29
 Tween 80, 95
 tyroservatide, 467
 TZT-1027, 905
- UFT, 709
 UGT1A1 polymorphism, 693
 Ukraine, 669
 ulcerative colitis, 1183
 ultrasound, 1149
 urothelial carcinoma, 1207
- vascular endothelial cells, 1
 vascular endothelial growth factor receptor inhibition, 349
 vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, 569
 vascular permeability, 905
 vascular targeting, 1189
 vascular targeting agent, 905
 vinorelbine, 1201
 vitamin D₃, 1183
- weekly, 227, 687
 weekly administration, 963
- xenograft, 377, 47, 1081